HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT

(19)

(11)

EP 0 988 059 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	01.03.2006 Bulletin 2006/09

(45)	Mention of the grant of the patent:
	07.12.2005 Bulletin 2005/49

(21)	Application number: 98929555.5

(22)	Date of filing: 15.06.1998

(51)

International Patent Classification (IPC):

A61K 47/48^(1990.01)
A61K 38/44^(1995.01)

A61P 35/00^(2000.01)
A61K 31/4422^(2000.01)

(86)	International application number:
	PCT/GB1998/001731

(87)	International publication number:
	WO 1998/057662 (23.12.1998 Gazette 1998/51)

(54)	HUMAN QUINONE REDUCTASE 2 CONJUGATES FOR ADEPT AND GDEPT MENSCHLICHE CHINON REDUKTASE KONJUGATE FÜR ADEPT UND GDEPT CONJUGES DE QUINONE-REDUCTASE HUMAIN POUR ADEPT ET GDEPT

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30)

Priority:

14.06.1997 GB 9712370

(43)	Date of publication of application:
	29.03.2000 Bulletin 2000/13

(60)	Divisional application:
	04076964.8 / 1468698

(73)	Proprietor: Protherics Molecular Design Limited
	Runcorn Cheshire WA7 4QF (GB)

(72)	Inventors:
	BURKE, Philip, John London SE7 7PF (GB) KNOX, Richard, John Sutton, Surrey SM1 2SU (GB)

(74)	Representative: Miles, John Stephen
	Eric Potter Clarkson LLP Park View House 58 The Ropewalk Nottingham NG1 5DD Nottingham NG1 5DD (GB)

(56)

References cited: :

WO-A-93/08288
WO-A-97/07097
WO-A-98/22577

WO-A-95/12678
WO-A-97/24143

KNOX R J ET AL: "THE BIOACTIVATION OF CB 1954 AND ITS USE AS A PRODRUG IN ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT)" CANCER AND METASTASIS REVIEWS, vol. 12, no. 2, 1993, pages 195-212, XP000618513 cited in the application
FRIEDLOS F ET AL: "METABOLISM OF NADPH BY BLOOD COMPONENTS RELEVANCE TO BIOREDUCTIVELY ACTIVATED PRODRUGS IN A TARGETED ENZYME THERAPY SYSTEM" BIOCHEM PHARMACOL, vol. 44, no. 4, 1992, pages 631-635, XP000618526 cited in the application
WU K ET AL: "Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase." ARCH BIOCHEM BIOPHYS, NOV 15 1997, 347 (2) P221-8, XP002080156 UNITED STATES
MELTON, R. G. ET AL: "Antibody-directed enzyme prodrug therapy (ADEPT). Review article" DRUGS OF THE FUTURE, vol. 21, no. 2, 1996, pages 167-184, XP002080157
SHERWOOD R F: "ADVANCED DRUG DELIVERY REVIEWS: ENZYME PRODRUG THERAPY" ADVANCED DRUG DELIVERY REVIEWS, vol. 22, 1996, pages 269-288, XP002064128
GREEN N. K. ET AL: "Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene" CANCER GENE THERAPY, vol. 4, no. 4, August 1997, pages 229-238, XP002092056
DRABEK D. ET AL: "The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954" GENE THERAPY, vol. 4, no. 2, February 1997, pages 93-100, XP002092057

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).